Table 4.
Clinicopathologic characteristics of lung adenocarcinoma patients with EGFR mutation, stratified by polymorphic genotypes of SOD rs4880.
| All Cases (n = 306) | L858R and Exon 19 Deletion (n = 189) | |||||||
|---|---|---|---|---|---|---|---|---|
| Variable | AA (n = 215) | AG + GG (n = 91) |
AOR (95% CI) | p Value | AA (n = 127) | AG + GG (n = 62) |
AOR (95% CI) | p Value |
| Stage | ||||||||
| I + II | 66 (30.7) | 15 (16.5) | 1.00 | 41 (32.3) | 10 (16.1) | 1.00 | ||
| III + IV | 149 (69.3) | 76 (83.6) | 2.24 (1.20–4.22) | 0.012 * | 68 (67.7) | 52 (83.9) | 2.40 (1.10–5.22) | 0.027 * |
| Tumor T status | ||||||||
| T1 + T2 | 134 (62.3) | 53 (58.2) | 1.00 | 84 (66.1) | 40 (64.5) | 1.00 | ||
| T3 + T4 | 81 (37.7) | 38 (41.8) | 1.18 (0.71–1.95) | 0.523 | 43 (33.9) | 22 (35.5) | 1.02 (0.53–1.95) | 0.951 |
| Lymph node status | ||||||||
| Negative | 76 (35.3) | 23 (25.3) | 1.00 | 48 (37.8) | 17 (27.4) | 1.00 | ||
| Positive | 139 (64.7) | 68 (74.7) | 1.63 (0.94–2.84) | 0.084 | 79 (62.2) | 45 (72.6) | 0.56 (0.80–3.30) | 0.195 |
| Distant metastasis | ||||||||
| Negative | 106 (49.3) | 33 (36.3) | 1.00 | 63 (49.6) | 22 (35.5) | 1.00 | ||
| Positive | 109 (50.7) | 58 (63.7) | 1.69 (1.01–2.80) | 0.044 * | 64 (50.4) | 40 (64.5) | 1.72 (0.92–3.25) | 0.092 |
| Tumor differentiation | ||||||||
| Well | 24 (11.2) | 7 (7.7) | 1.00 | 19 (15.0) | 5 (8.1) | 1.00 | ||
| Moderate + poor | 191 (88.8) | 84 (92.3) | 1.52 (0.63–3.69) | 0.353 | 108 (85.0) | 57 (91.9) | 1.98 (0.70–5.60) | 0.198 |
I + II is population of stage I and stage II, we compared early stage and advance stage. T1 + T2 is population of T1 and T2, this is only analysis tumor size and genetic variants association. AOR is the abbreviation of adjusted odds ratios, adjust gender and age. CI is the abbreviation of confidence interval. *: p value is less than 0.05.